AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against the coronavirus has shown “an average efficacy of 70%” in trials.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” AstraZeneca’s chief executive Pascal Soriot said in a statement.
The vaccine can prevent 70.4% of people from getting the virus and up to 90% if a lower dose is used, according to data from the biopharmaceutical firm.
However, the vaccine has produced less effective results when compared with others produced by rivals Pfizer/BioNTech and Moderna which have shown to be around 95% effective.
jsi/rt (dpa, AFP, AP)